Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

for
HR+/HER2- Breast Cancer
Location: Shirley NY, Stony Brook NY, Danbury CT, Mineola NY,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07492641

Phase 3, Recruiting

Trial of Spiritual Care Interventions for Patients With Cancer

for
Advanced Cancer
Location: New York NY, Galveston TX, Houston TX
Sponsor: Weill Medical College of Cornell University

Sex: All

Age: 18+

Code: NCT07408310

Recruiting

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

for
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT05208047

Phase 3, Recruiting

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

for
Breast Cancer, Peripheral Neuropathy
Location: The Bronx NY
Sponsor: Montefiore Medical Center

Sex: All

Age: 18+

Code: NCT07109817

Phase 2, Recruiting

JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

for
Cardiovascular Health, Breast Cancer,
Location: Toronto
Sponsor: Women's College Hospital

Sex: All

Age: 18 - 70+

Code: NCT06930521

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

for
Metastatic Breast Cancer
Location: Boston MA, New Haven CT
Sponsor: Sun Yat-sen University

Sex: Female

Age: 18 - 70+

Code: NCT06551220

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

for
Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic,
Location: Sherbrooke, New York NY, Pasadena MD, Camp Hill PA,
Sponsor: Apollo Therapeutics Ltd

Sex: All

Age: 18 - 65

Code: NCT07599813

Phase 2, Recruiting

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

for
Solid Tumor Malignancies, Testicular Cancer,
Location: Tucson AZ
Sponsor: University of Arizona

Sex: All

Age: 18+

Code: NCT07407582

Phase 1, Phase 2, Recruiting

Capecitabine in ER+/HER2-negative Breast Cancer

for
ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT07631052

Phase 2, Recruiting

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

for
Breast Cancer With Low to Intermediate HER2 Expression
Location: Rochester NY
Sponsor: University of Rochester

Sex: Female

Age: 18 - 70+

Code: NCT07630402

Recruiting

Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

for
Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05733091

Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Brewer ME, Providence RI, West Islip NY, Stamford CT,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07391774

Phase 3, Recruiting

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

for
Advanced HR+/HER2- Breast Cancer
Location: New Haven CT, Toronto, Kansas City KS, Dallas TX
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07604571

Phase 1, Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

for
Advanced Solid Tumor, Non-Small Cell Lung Cancer,
Location: Fairfax VA, Tampa FL, Sarasota FL
Sponsor: Blueprint Medicines Corporation

Sex: All

Age: 18+

Code: NCT07629960

Phase 1, Phase 2, Recruiting

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

for
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer,
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT05000294

Phase 1, Phase 2, Recruiting

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18 - 70+

Code: NCT04529044

Phase 2, Recruiting

Phase I Human Analytics (HALO) Study

for
Cardiovascular Diseases, Cancer, Dementia,
Location: Indian Wells CA
Sponsor: HALO Diagnostics

Sex: Male

Age: 45 - 70+

Code: NCT05423860

Recruiting

Oncoplastic Surgery Outcomes Database

for
Breast Cancer
Location: Boston MA
Sponsor: Tufts Medical Center

Sex: Female

Age: 18+

Code: NCT07597837

Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

for
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer,
Location: Fairfax VA, Denver CO, Sarasota FL, Nashville TN,
Sponsor: ArriVent BioPharma, Inc.

Sex: All

Age: 18+

Code: NCT07066657

Phase 1, Recruiting

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT05741164

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial